Last reviewed · How we verify
Adalimumab-EU
At a glance
| Generic name | Adalimumab-EU |
|---|---|
| Also known as | Humira |
| Sponsor | Pfizer |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- Headache
- Upper respiratory tract infection
- Nasopharyngitis
- Injection site reaction
- Injection site erythema
- Injection site pain
- Nausea
- Oropharyngeal pain
- Rhinitis
- Diarrhoea
- Fatigue
- Rhinorrhoea
Key clinical trials
- To Compare the Pharmacokinetics and Safety of PBP1502 and Humira in Healthy Subjects (PHASE1)
- To Compare Pharmacokinetics, Efficacy, and Safety of CT-P17 With Humira in Patients With Moderate to Severe Chronic Plaque Psoriasis (PHASE3)
- MSB11022 in Moderate to Severe Chronic Plaque Psoriasis (PHASE3)
- A Real-world Study of Imraldi® Use
- Pharmacokinetics, Safety and Tolerability Study of AVT02 to EU-approved and US-licensed Humira (Adalimumab) (PHASE1)
- Adalimumab PK Bioequivalence Study to EU and US Sourced Humira (PHASE1)
- To Compare the Pharmacokinetics and Safety of CT-P17 and Humira in Healthy Subjects (PHASE1)
- The Purpose of This Research Study is to Compare the Efficacy and Safety of SCT630 and Adalimumab (HUMIRA®) in Adults With Plaque Psoriasis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Adalimumab-EU CI brief — competitive landscape report
- Adalimumab-EU updates RSS · CI watch RSS
- Pfizer portfolio CI